Loading...
XNAS
NURO
Market cap9mUSD
Jan 08, Last price  
4.04USD
Name

NeuroMetrix Inc

Chart & Performance

D1W1MN
XNAS:NURO chart
P/E
P/S
2.74
EPS
Div Yield, %
Shrs. gr., 5y
74.71%
Rev. gr., 5y
-20.03%
Revenues
3m
-48.61%
34,298,13355,249,71644,622,21131,120,80026,137,02613,899,67010,396,7757,575,2895,278,8065,512,7647,299,83012,027,52817,092,33616,090,1389,272,5227,377,9758,253,4938,256,0735,901,4253,032,837
Net income
-8m
L+19.55%
938,2584,267,806-8,378,474-27,730,049-11,917,500-16,891,148-9,981,105-10,007,553-8,019,137-7,766,222-9,187,348-14,913,151-12,859,25323,605-3,649,002-2,002,241-2,205,079-4,367,218-6,529,487-7,806,055
CFO
-7m
L+17.15%
1,908,0907,297,903-7,989,115-10,688,463-6,137,087-13,307,114-6,778,398-9,175,567-6,554,908-7,678,493-13,099,853-15,080,276-12,652,3842,861,713-3,621,253-2,066,861-2,073,694-5,289,416-6,084,868-7,128,353
Dividend
Mar 28, 20070.15 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
IPO date
Jul 22, 2004
Employees
27
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT